Adoptive immunotherapy for cancer: building on success Substantial progress has been made in our understanding of the molecular and cellular bases of T cell mediated anti-tumor responses. T cells are potent effectors of the adaptive anti-tumor immune response. Some target antigens recognized by tumor-reactive CD8+ T cells are non-mutated self-antigens that are also expressed by tumor cells. The molecular signals that modulate T cell activation, function and memory are being elucidated. Both positive and negative signals from co-stimulatory molecules have been shown to shape the anti-tumor response. Cytokines, including those with receptors that contain the common cytokine-receptor gamma chain have been shown to alter the programming of effector CD8+ T cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010763-06
Application #
8349144
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2011
Total Cost
$1,380,074
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Lin, Cheng-Chao; Kurashige, Mahiro; Liu, Yi et al. (2018) A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed. Sci Rep 8:2743
Henning, Amanda N; Klebanoff, Christopher A; Restifo, Nicholas P (2018) Silencing stemness in T cell differentiation. Science 359:163-164
Henning, Amanda N; Roychoudhuri, Rahul; Restifo, Nicholas P (2018) Epigenetic control of CD8+ T cell differentiation. Nat Rev Immunol 18:340-356
Vizcardo, Raul; Klemen, Nicholas D; Islam, S M Rafiqul et al. (2018) Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System. Cell Rep 22:3175-3190
Kishton, Rigel J; Sukumar, Madhusudhanan; Restifo, Nicholas P (2017) Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab 26:94-109
Sukumar, Madhusudhanan; Kishton, Rigel J; Restifo, Nicholas P (2017) Metabolic reprograming of anti-tumor immunity. Curr Opin Immunol 46:14-22
Gurusamy, Devikala; Clever, David; Eil, Robert et al. (2017) Novel ""Elements"" of Immune Suppression within the Tumor Microenvironment. Cancer Immunol Res 5:426-433
Wang, Qiong J; Yu, Zhiya; Hanada, Ken-Ichi et al. (2017) Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. Clin Cancer Res 23:2267-2276
Slaney, Clare Y; von Scheidt, Bianca; Davenport, Alexander J et al. (2017) Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. Clin Cancer Res 23:2478-2490
Afzali, Behdad; Grönholm, Juha; Vandrovcova, Jana et al. (2017) BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. Nat Immunol 18:813-823

Showing the most recent 10 out of 128 publications